suma/neoplasms

FIELD OF THE INVENTION The present invention provides amorphous and crystalline forms of sorafenib acid addition salts, process for their preparation, pharmaceutical compositions comprising them and their use for the treatment of cancer. The present invention also provides a process for the

FIELD OF THE INVENTION The present invention provides amorphous and crystalline forms of sorafenib acid addition salts, a process for their preparation, pharmaceutical compositions comprising them, and their use for the treatment of cancer. The present invention also provides a process for the

FIELD OF THE INVENTION Description of the Text File Submitted Electronically The contents of the text file submitted electronically herewith are incorporated by reference in their entirety. A computer readable format copy of the Sequence Listing (filename: NEWL_012_05US_SeqList.txt, date recorded

FIELD OF THE INVENTION Description of the Text File Submitted Electronically The contents of the text file submitted electronically herewith are incorporated by reference in their entirety. A computer readable format copy of the Sequence Listing (filename: NEWL.sub.--012.sub.--02US_SeqList.txt, date

FIELD OF THE INVENTION The present invention relates to methods and compositions for treating cancer by stimulating humoral and cellular immune responses against tumor cells. In particular, this invention is directed to methods and compositions to enhance the humoral and cellular immunogenicity of

FIELD OF THE INVENTION Description of the Text File Submitted Electronically The contents of the text file submitted electronically herewith are incorporated by reference in their entirety. A computer readable format copy of the Sequence Listing (filename: NEWL.sub.--012.sub.--03US_SeqList.txt, date

BACKGROUND OF THE INVENTION The invention relates to addition products between .alpha.-keto-aldehydes and secondary amines .alpha.-KETO-ALDEHYDES ARE WELL KNOWN AND USUALLY ARE PREPARED THROUGH OXIDATION (Riley, H. L., Morley, J. F., and Friend, N.A.C.: J.Chem.Soc. 1932.1875; Rabjohn, N.: in Organic

BACKGROUND OF THE INVENTION This invention relates to a novel N-acetyl substituted aryl analog of an N-substituted benzamide, its acid addition salts, the use thereof as direct chemotherapeutic agents or as sensitizers for radiation and/or other chemotherapeutic agents in methods of inhibiting or

The invention relates to acid addition salts and/or solvates of [6-hydroxy-2-(4-hydroxyphenyl)benzol[1)]thien-3-yl][4-[2-(1-piperidinyl)-- ethoxy]phenyl-, raloxifene, having high availability from media comprising dilute hydrochloric acid, such as gastric juice. In addition useful crystal forms of

BACKGROUND OF THE INVENTION A key step in the formation of the nervous system is the determination of proliferating neural progenitor cells to undergo differentiation into neurons and glia. Despite major advances in identification and characterization of neural progenitor cells (Placzek and Furley,

FIELD OF THE INVENTION The present invention relates to acid addition salts of the pharmaceutically active compound (3,5-Bistrifluoromethyl)-N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamin- o)-phenyl]-benzamide(I): ##STR00002## Development Code--AN019 The invention also relates to processes for the

DESCRIPTION The present invention relates to a method of treating cancer and cancer metastasis using 5-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine or a salt thereof as active ingredient. 5-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine is a compound represented by the formula:

FIELD OF THE INVENTION The present invention relates to vaccines and methods for treating a disease, such as cancer. More specifically, the present invention relates to immunogenic cells which act to stimulate and induce an immunogenic response to an antigen, such as a tumor associate antigen

BACKGROUND OF THE INVENTION This invention relates to methods of inhibiting or killing tumor and cancer cells in human patients using aryl N-substituted carboxamides such as N-substituted benzamides and nicotinamides as direct chemotherapeutic agents or as sensitizers for radiation and/or other

SEQUENCE LISTING The instant application contains a Sequence Listing which has been submitted via EFS-web and is hereby incorporated by reference in its entirety. The ASCII copy, created on Oct. 29, 2013, is named 1-55242-D2013-86_SL.txt, and is 8,959 bytes in size. A brief description of the